Showing 5141-5150 of 7030 results for "".
- Anti-C5a Antibody Vilobelimab for HS to Be Presented at EADVhttps://practicaldermatology.com/news/anti-c5a-antibody-vilobelimab-hs-be-presented-eadv/2468302/InflaRx N.V. announced the e-poster presentation of a post hoc analysis of the SHINE Phase 2b study of its first-in-class anti-C5a antibody, vilobelimab, in hidradenitis suppurativa (HS) at the 2024 European Academy of Dermatology and Venereology (EADV) Congress being held in Amsterdam, Netherlan
- Kenvue to Present New Data Sets at EADV Congresshttps://practicaldermatology.com/news/kenvue-present-new-data-sets-eadv-congress/2468301/Kenvue announced the presentation of seven new data sets at the 2024 European Academy of Dermatology and Venereology (EADV) Congress this week in Amsterdam, Netherlands. The studies will feature Kenvue’s Aveeno and Neutrogena brands, “demonstrating the key to improved skin and hair outcome
- Frontier Acquires Mohs Specialist Doherty Dermatologyhttps://practicaldermatology.com/news/frontier-acquires-mohs-specialist-doherty-dermatology/2468264/Frontier Dermatology announced the acquisition of Doherty Dermatology, a clinic in Bellingham, Washington, that specializes in Mohs micrographic surgery. Doherty Dermatology will be rebranded as Frontier Dermatology (Bellingham South) starting October 1, joining the company's 35 other physician o
- sNDA Accepted for Roflumilast Foam 0.3% for Psoriasishttps://practicaldermatology.com/news/snda-accepted-roflumilast-foam-03-psoriasis/2468261/The US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for roflumilast foam 0.3%—a once-daily, next-generation phosphodiesterase-4 (PDE4) inhibitor branded ZORYVE by Arcutis Biotherapeutics, Inc.—for the treatment of adults and adolescents ages 12 and ov
- Delgocitinib for CHE Gains EC Approval, FDA NDA Acceptancehttps://practicaldermatology.com/news/delgocitinib-che-gains-ec-approval-fda-nda-acceptance/2468259/Delgocitinib cream 20 mg/g (2%) reached major milestones in both the United States and Europe, LEO Pharma Inc. announced. The US Food and Drug Administration (FDA) accepted a filing for a New Drug Application (NDA) for LEO Pharma’s AnzupgoÒ for the treatment of adults with moderate-to-seve
- Almirall to Present New Drug Data at EADVhttps://practicaldermatology.com/news/almirall-present-new-drug-data-eadv/2468258/Almirall will present 34 abstracts detailing the latest research on lebrikizumab for moderate-to-severe atopic dermatitis in adolescents and adults and tildrakizumab and Almirall’s CAL/BDP cream for moderate-to-severe plaque psoriasis in adults at the 33rd Congress of the European Academy of Derm
- NJ Legislator Pushes to Allow Sunscreen in Schoolshttps://practicaldermatology.com/news/nj-legislator-pushes-allow-sunscreen-schools/2468244/A new bill referred to New Jersey’s Assembly Education Committee would make the Garden State the 29th to pass legislation allowing direct access to sunscreen in schools, according to Insider NJ. Sunscreen is classified by the US Food and Drug Administration (FDA) as an over-the-counter dru
- Study Links Psoriasis to NMSC in Womenhttps://practicaldermatology.com/news/study-links-psoriasis-nmsc-women/2468243/Psoriasis was associated with a higher risk of nonmelanoma skin cancer in women in a new study published in Nature Communications. “An observational and genetic investigation into the association between psoriasis and risk of malignancy” found higher risks of a total of 16 types of cancer
- ASDS Hosts New 'Expertise Summit'https://practicaldermatology.com/news/asds-hosts-new-expertise-summit/2468191/More than 50 dermatologic surgeons and dermatology residents gathered in Chicago, Illinois, on September 7-8 for a new course from the American Society for Dermatologic Surgery (ASDS), titled “ASDS Expertise Summit: Surgery. Injectables.” Practical Dermatology Editorial Board member Dr. As
- Eczema Patients at Higher Risk for Comorbidities, Study Findshttps://practicaldermatology.com/news/eczema-patients-higher-risk-comorbidities-study-finds/2468064/Recent analysis of data from the NIH’s All of Us Research Program reveals significant associations between atopic dermatitis (AD) and other health conditions, underscoring the multifaceted burdens faced by AD patients. The All of Us Research Program, which collected health data from over 8